Protalix BioTherapeutics, Inc. (PLX) Free cash flow 2016–2025
Protalix BioTherapeutics, Inc. (PLX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$13.6MFY2025 · since FY2016: -$32.9M → -$13.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$13.6M | -284.4% |
| FY2024 | $7.4M | +399.6% |
| FY2023 | -$2.5M | +90.4% |
| FY2022 | -$25.6M | -118.2% |
| FY2021 | -$11.7M | +56.1% |
| FY2020 | -$26.8M | -33.9% |
| FY2019 | -$20.0M | -137.1% |
| FY2018 | -$8.4M | +23.1% |
| FY2017 | -$11.0M | +66.7% |
| FY2016 | -$32.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice